Covid vaccine, Pfizer completes phase 3 analysis and announces: “95% effective”. Moderna gave her candidate 94.5% two days ago

In the rush for the vaccine anti-Covid today is the turn of Pfizer-Biontech: the American pharmaceutical company announces that it has completed phase 3 of the trial and announces that its candidate is “effective in 95% and does not produce serious side effects“The percentage is even higher than the first estimate of 90% given a week ago based on interim results. And above all, it temporarily places Pfizer on the top step of the podium in the world race: just two days ago, on November 16, Modern gave its 94.5% efficiency.

The company has entered into agreements with the EU for 160 million doses and if the deal were to end, Brussels would reach the sixth contract after those stipulated with pharmaceutical companies Curevac, AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica and with the same Pfizer-BionTech, which today announces its new data. As the New York Times, the numbers presented by Pfizer are the result of the first complete series of results from an advanced stage trial and showed that the vaccine prevented mild and severe forms of COVID-19 and it was also 94% effective in Old people, more vulnerable to developing severe SARS-Cov-2 and less likely to have a complete response to some types of vaccines.

Pfizer, who developed the possible vaccine with their partner BionTech, announced that the two companies plan to request emergency authorization for Food and Drug Administration (FDA) American “in a few days”: if the Fda will authorize it, Pfizer He explained that it could have up to 50 million doses available by the end of the year and up to 1.3 billion by the end of next year. About half of the supply will go to United States this year, enough for around 12.5 million people (out of 330 million). Americans will get the vaccine free, under a $ 1.95 billion agreement that the federal government reached with Pfizer per 100 million doses. “The study findings mark an important step in this historic eight-month journey toward a vaccine that can help end this devastating pandemic,” he said in a statement. Albert bourla, managing director of Pfizer.

The experimentation included almost 44 thousand volunteers. Pfizer me BionTech you now intend to post the results for your review in a scientific magazineThis process can take weeks or months. In addition to data from its clinical trials, the giant said it was ready to submit two months of safety data to the US FDA, as well as detailed production documents showing that the company can consistently produce high-quality batches. of your vaccine. There Fda will review the data and request an external group of experts to evaluate the authorization request, a process that according to the New York Times it could take weeks. If the vaccine is licensed, storage and administration will proceed.